JAK kinases classically signal by activating STAT transcription factors, but can also regulate gene expression by epigenetically phosphorylating histone H3 on tyrosine 41 (H3Y41-P). In diffuse large B cell lymphomas (DLBCL), JAK signaling is a feature of the ABC subtype and is triggered by autocrine production of IL-6 and IL-10. Whether this signaling involves STAT activation, epigenetic modification of chromatin or both mechanisms is unknown. Here we use genetic and pharmacological inhibition to show that JAK1 signaling sustains the survival of ABC DLBCL cells. While STAT3 contributed to the survival of ABC DLBCL cell lines, forced STAT3 activity could not protect these cells from death following JAK1 inhibition, suggesting epigenetic JAK1 action. JAK1 regulated the expression of nearly 3,000 genes in ABC DLBCL cells, and the chromatin surrounding many of these genes was modified by H3Y41-P marks that were diminished by JAK1 inhibition. These JAK1 epigenetic target genes encode important regulators of ABC DLBCL proliferation and survival, including IRF4, MYD88 and MYC. A small molecule JAK1 inhibitor cooperated with the BTK inhibitor ibrutinib in reducing IRF4 levels and acted synergistically to kill ABC DLBCL cells, suggesting that this combination should be evaluated in clinical trials.
Introduction
Diffuse large B cell lymphoma (DLBCL), a B cell non-Hodgkin lymphoma, represents 30% to 40% of newly diagnosed lymphomas, and includes two main molecular subtypes termed activated B cell-like (ABC) and germinal center B cell-like (GCB) (1, 2) . ABC DLBCL is more aggressive, with a current cure rate of only ~40% (3) . One distinct feature of this lymphoma is autocrine signaling mediated by the cytokines IL-6 and IL-10, which constitutively activates the transcription factor STAT3 (4) (5) (6) . Autocrine production of these cytokines results from high NF-κB activity (7) , which is a hallmark of ABC DLBCL (4, (8) (9) (10) . The NF-κB pathway can be engaged by a variety of genetic alterations in ABC DLBCL (9, 11, 12) , including somatic mutations targeting components of the B cell receptor (BCR) and Toll-like receptor (TLR) signaling pathways. For example, 39% of ABC DLBCL tumors have mutations in the gene encoding MYD88, a key signaling adaptor in Toll-like receptor signaling (9) . The most prevalent MYD88 mutation (L265P), which is present in 29% of ABC DLBCL tumors, promotes cell survival by engaging the NF-κB pathway and inducing production of IL-6 and/or IL-10. NF-κB is also activated in ABC DLBCL by gain-of-function mutations in the B cell receptor (BCR) pathway, including mutations targeting the BCR components CD79A and CD79B (11) and the downstream signaling adaptor CARD11 (13) . Targeting BCR signaling with ibrutinib, a specific inhibitor for Bruton tyrosine kinase (BTK), has emerged as a promising therapy for ABC DLBCL (14) .
IL-6 and IL-10 function through their respective receptors and activate members of the Janus kinase (JAK) family (15, 16) . In mammals, the JAK family has 4 members: JAK1, JAK2, JAK3, and TYK2 (15) . JAKs phosphorylate STAT family members to promote STAT dimerization, nuclear translocation, and binding to cis-regulatory elements to regulate transcription (15, 17) . This canonical JAK/STAT pathway is deregulated in several hematologic malignancies (16) . In DLBCL, STAT3 is activated in the ABC subtype and regulates gene expression to promote the survival of the malignant cells (6, 18) .
A separate, non-canonical mechanism by which JAK activity perturbs gene expression is by directly phosphorylating chromatin, which was first discovered in Drosophila (19) and subsequently confirmed in human cells (20) (21) (22) . In leukemia cells, a mutant JAK2 isoform phosphorylates the tail of histone H3 tyrosine 41 (H3Y41), which displaces the inhibitory heterochromatin protein HP1α from chromatin to augment gene transcription (20, 23) . We previously reported a similar function of JAK2 in primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL), in which JAK2 kinase is activated by autocrine IL-13 signaling (21, 24) . Through this non-canonical pathway, JAK2 induces expression of more than 2,000 genes, including genes that control the growth and proliferation of the malignant cell such as MYC, JMJD2C, and JAK2 itself, as well as the genes encoding PD-L1 and PD-L2, which inhibit tumor immunity through the T cell inhibitory receptor PD1 (21, 24, 25) .
Here, we demonstrate that JAK1 promotes the malignant phenotype of ABC DLBCL cells by phosphorylating and activating STAT3 and also epigentically by phosphorylating chromatin on H3Y41. We demonstrate that some epigenetic JAK1 target genes are also induced by the BCR/NF-κB signaling pathway and that co-targeting of BCR and JAK signaling with small molecule inhibitors kills ABC DLBCL cells synergistically.
Results

JAK1 is required for the survival of ABC DLBCL cells.
The essential role of autocrine IL-6 or IL-10 signaling in the survival of ABC DLBCL cells has been demonstrated (4, 5) , but the molecular mechanisms by which these cytokines promote lymphomagenesis are largely unknown. As a first step, we examined the viability of DLBCL cell lines treated with AZD1480, an inhibitor of JAK1 and JAK2 (26) . AZD1480 potently decreased cell viability in ABC but not GDC DLBCL lines (Fig. 1A) , and induced apoptosis in ABC DLBCL lines, as indicated by active caspase 3 and cleaved PARP (Fig. 1B) . Selective toxicity to ABC DLBCL cell lines was also observed with another inhibitor of JAK1 and JAK2, ruxolitinib (Fig. 1A) (27) . Since JAK2 is not activated in ABC DLBCL cells (21), we tested whether JAK1 is the target of AZD1480 action in these lymphomas. Due to the difficulty in detecting JAK1 phosphorylation by a direct immunoblotting assay, we first immunoprecipitated tyrosine-phosphorylated proteins and then immunoblotted with an antibody that detects JAK1 phosphorylation. By this method, JAK1 phosphorylation was evident in all ABC DLBCL cell lines tested and was reduced when cells were treated with AZD1480 (Fig. 1C) .
To investigate the consequence of JAK1 activity in ABC DLBCL, we developed JAK1-specific small hairpin RNAs (shRNAs) that mediate RNA interference and expressed them using a retroviral vector that co-expresses green fluorescent protein (GFP). We identified two shRNAs that reduced JAK1 expression by 50% to 70% (Fig. S1A and B) . Following retroviral infection, the percentage of viable shRNA-expressing (GFP+) cells relative to day 0 was monitored over time by fluorescence activated cell sorting (FACS). Over the course of 12 days, JAK1 shRNA expression decreased the viability of all 6 ABC DLBCL lines examined, whereas two GCB DLBCL lines were insensitive (Fig.   1D ). By contrast, the viability of ABC DLBCL cells was not affected by a JAK2 shRNA (Fig. S1C) , which is toxic for JAK2-dependent PMBL and HL cell lines (21) . Together, these data demonstrate that JAK1 promotes ABC DLBCL cell survival.
JAK1-mediated H3Y41 phosphorylation and epigenetic gene regulation in ABC DLBCL.
We and others have demonstrated that ABC DLBCL cell survival is promoted by overexpression and activation of STAT3 by autocrine IL-6 and IL-10 signaling (4-6). We therefore investigated whether a constitutively activated form of STAT3 (STAT3-C) (28) would prevent the apoptotic cell death induced by JAK1 inhibition. STAT3-C forms a dimer that is driven by oxidation of cysteines rather than by JAK-mediated phosphorylation of tyrosine 705, and can transform fibroblasts (28, 29) . We used a retrovirus to express STAT3-C in two ABC DLBCL lines, TMD8 and HBL1, and immunoblot analysis demonstrated that STAT3-C increased the levels of active, phosphorylated STAT3 ( Fig. 2A, left) . To test the ability of STAT3-C to promote ABC DLBCL survival, we knocked down endogenous STAT3 expression using an shRNA targeting the STAT3 3' untranslated region in two ABC DLBCL lines that had been transduced with either STAT3-C or an empty vector. In cells transduced with empty vector, STAT3 knockdown caused a time-dependent loss of viable cells, but this was reversed by expression of STAT3-C (Fig. 2B) . By contrast, in two ABC DLBCL lines induced to express a JAK1 shRNA, expression of STAT3-C produced partial or no rescue of viability, whereas ectopic expression of JAK1 itself was able to rescue the cells (Fig. 2C ).
These findings suggested that STAT3 mediates some but not all of the pro-survival function of JAK1 in ABC DLBCL cells, prompting us to investigate the role of non-canonical JAK signaling in these cells. First, we investigated the subcellular distribution of JAK1 in ABC DLBCL cell lines.
JAK1 was detected in cytoplasmic fractions enriched for tubulin but also in nuclear extracts enriched for histone H3, consistent with the possibility of non-canonical JAK1 signaling in the nucleus (Fig.   3A ). Since non-canonical JAK2 signaling in PMBL and HL promotes expression of MYC (21), we investigated whether this is also true for JAK1 in ABC DLBCL. Immunoblot analysis revealed that MYC expression was strongly reduced following knockdown of JAK1 in ABC DLBCL cells, but was not affected by knockdown of JAK2 (Fig. 3B) . The small molecule JAK1 inhibitors AZD1480 and ruxolitinib also significantly reduced MYC expression in a dose-dependent manner (Fig. 3C) .
Moreover, these inhibitors decreased global H3Y41 phosphorylation, consistent with non-canonical JAK1 signaling (Fig. 3C ).
We next investigated H3Y41 phosphorylation at the MYC locus by chromatin immunoprecipitation (ChIP) and quantitative PCR analysis using primers spanning several regulatory regions of the MYC locus, as described (21) . We performed this analysis in TMD8 ABC DLBCL cells treated with the JAK1 inhibitor AZD1480 or with DMSO as a control. H3Y41 phosphorylation was evident at several MYC regions, and AZD1480 reduced these ChIP signals. The largest effect was observed at a regulatory region in intron 1 ( Fig. 3D ) that is also phosphorylated by JAK2 in PMBL and HL cells (21) . These data suggest that the potent upregulation of MYC by JAK1 is a consequence of H3Y41 phosphorylation of the MYC locus.
Identification of JAK1 target genes by H3Y41-P ChIP-seq in ABC DLBCL.
To identify the targets of non-canonical JAK1 signaling genome-wide, we performed H3Y41-P ChIP coupled with next-generation sequencing (ChIP-Seq) in the ABC DLBCL cell line TMD8.
Using a stringent filter for peak calling, we identified a total of 36,634 H3Y41-P peaks (Dataset S1), with the vast majority (70.3%) mapping near a protein-coding gene within a window extending from -15 kilobases (kb) 5' of the transcriptional start site (TSS) to the 3' end of any annotated transcript associated with the gene. Of those peaks, 36.3% were located upstream of the proximal promoter (-15 kb to -2 kb relative to the TSS), 21.4% were within the proximal promoter region (-2 kb to + 2 kb relative to the TSS), and the remaining 42.3% mapped within the gene body (+2 kb to the 3' end of annotated transcripts) (Fig. 4A ). Similar results were obtained when peak calling was performed at a different stringency, confirming that the observed genomic distribution reflects an intrinsic characteristic of H3Y41-P and does not depend on the height of the peaks considered for the analysis.
Notably, treatment of TMD8 cells with the JAK inhibitor AZD1480 reduced H3Y41-P modification at the majority of these genomic locations (Fig. 4C) . Peaks in the upstream, promoter and gene body regions were similarly affected by AZD1480 treatment (Fig. 4C , bottom panels), consistent with a global impairment of non-canonical JAK1 signaling. Notably, less than 1% of H3Y41-P bound sites (269/36,634) have a STAT binding motif.
We identified a total of 4,366 H3Y41-P peaks (associated with 2,956 genes) that were significantly reduced by AZD1480 treatment (P <0.01, see Methods for detail) (Dataset S1). This gene regulation mechanism by JAK1 is distinct from the canonical pathway since there is no statistical enrichment of the STAT motif within H3Y41-P peaks and more than 90% (2686/2956) of corresponding genes do not bear a STAT motif in their promoter region (Dataset S1). To functionally validate the role of H3Y41-P in the expression of these genes, we performed a time course analysis of gene expression changes resulting from AZD1480 treatment of TMD8 cells. Notably, genes with H3Y41-P peaks were enriched among genes that were downregulated by AZD1480 in TMD8 cells (P<0.0003, Fischer's exact test) but not among genes up-regulated by AZD1480 treatment (Fig. 4D ).
Gene Set Enrichment Analysis (GSEA) confirmed a significant enrichment of H3Y41-P+ genes among those whose transcription was blocked following JAK1 inhibition (P=2.92 x10 -7 , KolmogorovSmirnov test; Fig. 4E ). In parallel, we performed GSEA using a database of signatures that reflect signaling and regulatory processes in normal and malignant hematopoietic cells (30) . As expected, genes downregulated by AZD1480 treatment were strongly enriched for JAK/STAT-dependent genes, as well as for NF-κB target genes (Fig. 4F) . Altogether, these findings suggest that JAK1-dependent H3Y41 phosphorylation contributes to the transcriptional output of JAK1 signaling.
Representative genes with JAK1-dependent H3Y41-P peaks are shown in Figure 4G , including some that are known to be central to ABC DLBCL biology, such as MYC, IRF4, SPIB and MYD88.
Reduced IRF4 and MYD88 protein and mRNA expression after JAK1 inhibition was confirmed by immunoblot analysis and quantitative PCR in two ABC DLBCL cell lines (Fig. 4H) . To test whether MYC, IRF4 and MYD88 are regulated by conventional, JAK1-induced STAT3 activation, we knocked down expression of STAT3 with an shRNA or expressed the constitutively active STAT3-C isoform in ABC DLBCL cells and then analyzed expression of MYC, IRF4 or MYD88 by immunoblotting.
MYC expression was not altered in cells expressing either the STAT3 shRNA or STAT3-C, but was downregulated by a JAK1 shRNA or by AZD1480 treatment (Fig. S2A and B) . Similar results were obtained for IRF4 and MYD88 ( Fig. S2C and D) . Thus, these JAK1 target genes are regulated in a STAT3-independent fashion, consistent with non-canonical epigenetic regulation by JAK1. Other genes of note with H3Y41-P peaks that were downregulated by JAK1 inhibition (Fig. 4G ) encode the transcription factors JUN and JUND, which may contribute to ABC DLBCL survival (31); EGR1, an early growth response gene that is induced by BCR stimulation and promotes B cell proliferation and differentiation (32, 33) ; SPHK2, which is a molecular target in primary effusion lymphoma (34); ZFP36, an RNA binding protein that regulates mRNA stability (35) ; and SOCS3, a negative regulator of JAK1 signaling (36) .
Co-targeting JAK1 and BTK in ABC DLBCL.
The transcription factor IRF4 is a master regulator of the ABC DLBCL phenotype and is a target of both JAK1 signaling (see above) and chronic active BCR signaling in ABC DLBCL (10) . We therefore hypothesized that combined inhibition of JAK1 and BCR signaling would have synergistic toxicity in ABC DLBCL. To test this, we measured viability of two ABC DLBCL lines, TMD8 and OCI-Ly10, and a control GCB DLBCL line OCI-Ly19, following treatment with AZD1480 and/or ibrutinib, a BTK inhibitor that blocks BCR-dependent NF-κB activation. As expected, we observed a dose-dependent toxicity of ibrutinib treatment in the TMD8 and OCI-Ly10 lines but not in OCI-Ly19 (Fig. S3) . Data in Fig. 5A were normalized both to the viability of cells at time 0 and to the viability of cells treated with the indicated concentrations of ibrutinib alone. Addition of ibrutinib to AZD1480 shifted the viability curves for the two ABC DLBCL lines to the left, indicating more than additive killing by the combination, whereas these drugs had no effect on the viability of the GCB DLBCL lines (Fig. 5A) . Similarly, when JAK1 was knocked down using an shRNA in ABC DLBCL lines, the toxicity was increased by the addition of ibrutinib, but no toxicity of this combination was observed in a GCB DLBCL line (Fig. 5B) .
We next investigated whether decreased IRF4 levels were related to the combined toxicity of the JAK1 and BCR signaling inhibitors. Immunoblot analysis revealed a dose-dependent reduction in IRF4 levels with AZD1480 treatment, and the addition of ibrutinib decreased IRF4 levels further (Fig.   5C ). By contrast, another JAK1 target, MYD88, was decreased in expression by AZD1480, as expected, but the addition of ibrutinib did not decrease MYD88 levels further, in keeping with the fact that MYD88 levels are not regulated by BCR signaling (Fig. 5C) . Thus, decreased levels of the master regulatory transcription factor IRF4 could explain, at least in part, the observed synergistic killing of ABC DLBCL cells by JAK1 and BCR signaling inhibitors.
Discussion
Here we report a novel molecular mechanism by which JAK1 contributes to the malignant is activated by recurrent somatic mutations in ABC DLBCL, and the ABC DLBCL lines tested harbor the MYD88 L265P allele (9) . MYD88 signaling activates the NF-κB and p38 MAP kinase pathways, both of which promote the expression of IL-6 and IL-10, which initiate autocrine signaling and activate JAK1. Thus, epigenetic regulation of MYD88 by JAK1 initiates a positive feedback loop. In addition to IL-6 and IL-10, MYD88 induces many other NF-κB target genes, which most likely contribute to survival of ABC DLBCL cells (9) . Conversely, MYD88 signaling in ABC DLBCL also activates type I interferon expression, which is toxic for these cells (10) . IRF4 suppresses this type I interferon axis by repressing IRF7, a key transcriptional activator of type I interferon genes (10) . Of note, this function of IRF4 requires its dimerization with SPIB, which is also an epigenetic target of JAK1 in ABC DLBCL cells (10) . An additional important action of IRF4/SPIB is to upregulate CARD11, a key signaling adapter that is responsible for NF-κB activation downstream of BCR signaling (10).
Thus, the epigenetic regulation of IRF4 and SPIB by JAK1 in ABC DLBCL accentuates the prosurvival NF-κB pathway while dampening the pro-death type I interferon pathway.
Our study adds to a growing literature demonstrating epigenetic regulation of gene expression by JAK kinases, which followed the initial discovery that the Drosophila JAK homolog Hopscotch regulates development by preventing heterochromatin formation (19, 37) . This non-canonical mechanism of JAK signaling was further characterized in human leukemia and lymphoma cells in which nuclear JAK2 directly phosphorylates H3Y41, thereby blocking recruitment of the heterochromatin protein HP1α (20, 21) . In embryonic stem cells, H3Y41 is phosphorylated by both JAK1 and JAK2 and this is essential for self-renewal (22) . In ABC DLBCL, JAK1 epigenetic targets are largely non-overlapping with a set of STAT3 target genes defined in ABC DLBCL by integrated STAT3 ChIP-Seq with RNA-Seq analysis (18) . Of these STAT3 target genes in ABC DLBCL, most (1241/1540, 80.5%) do not have H3Y31-P peaks. Conversely, of the genes that have H3Y41-P peaks in ABC DLBCL and were downregulated by AZD1480 treatment, most (79/113, 70%) were not identified as STAT3 target genes. For example, the JAK1 epigenetic target gene IRF4 does not appear to be a target of STAT3 since its expression remains unchanged when STAT3 is knocked down or overexpressed (Fig. S2) . STAT3 transactivates the genes encoding IL-6 and IL-10, thereby augmenting both the canonical JAK1/STAT3 pathway as well as the non-canonical, JAK1 epigenetic pathway. In addition, STAT3 reinforces the canonical pathway by positively autoregulating its own expression (18) . STAT3 also regulates a number of genes that are also regulated by NF-κB, including NFKBIA, NFKBIZ, CXCR5, CD44, and PIM2 (18) , which could be due to the ability of STAT3 to form complex with NF-κB transcription factors (38) . We conclude that JAK1 uses STAT3-dependent and STAT3-independent regulatory mechanisms to influence the malignant phenotype of ABC DLBCL cells.
Our study supports the development of JAK1 inhibitors for the treatment of ABC DLBCL. We demonstrated that JAK1, not JAK2, is required for ABC DLBCL survival, which suggests that JAK1- (14), most responses were not long lasting, suggesting that combinations of targeted agents that inhibit distinct survival pathways will be necessary. Here we provide a rational basis for combining JAK1 inhibitors with inhibitors of BCR signaling that block NF-κB activation, such as ibrutinib. We identified IRF4 as a direct target of JAK1 epigenetic regulation, and IRF4 is also a target of NF-κB downstream of BCR signaling in ABC DLBCL. As a consequence, IRF4 levels are reduced in ABC DLBCL cells by treatment with ibrutinib (10) . The combination of the JAK1 inhibitor AZD1480 and ibrutinib cooperated to reduce IRF4 to undetectable levels, which most likely contributes to their synergy in killing ABC DLBCL cells. Our findings support the development of JAK1 inhibitors in conjunction with ibrutinib for the treatment of ABC DLBCL.
Materials and Methods
Full details of the methods used and data analysis are presented in SI Text.
Cell lines and culture. All doxycycline-inducible human DLBCL cell lines that express the bacterial tetracycline repressor were engineered as described previously (40) . Doxycycline (20 ng/ml) was used to induce the expression of genes or shRNAs of interest. All cultures were routinely tested for mycoplasma contamination.
ChIP-Seq analysis of H3Y41 phosphorylation. ChIP-enriched DNA samples were used to create adapter-ligated libraries for massively parallel sequencing with the ChIP-Seq DNA Sample Prep Kit (Illumina) following manufacturer's protocol, as described previously (21) . All ChIP-Seq data are available at http://www.ncbi.nlm.nih.gov/geo/ (accession # GSE86264).
Gene expression. Gene expression profiling was performed using Agilent 4X44K whole genome arrays, as described previously (21) . Signal from DMSO control cells (Cy3) was compared to JAK inhibitor-treated cells (Cy5). Array data are available at http://www.ncbi.nlm.nih.gov/geo/ (accession # GSE86265). +500 bp -500 bp +500 bp -500 bp +500 bp -500 bp +500 bp -500 bp Peak apex +500 bp -500 bp +500 bp -500 bp DMSO JAK inh. + e e e e e e e e e e e e e e e e e e e e e e e OCI-Ly10 
